China
Kelun-Biotech’s Twice-Yearly Asthma Candidate SKB378 Advances into Phase III
The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. ...
September 10, 2026 | News
Alebund Secures US FDA IND Clearance for First-in-Class IgA Nephropathy Therapy AP308
Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, announced that it has recen...
September 10, 2026 | News
Harbour BioMed’s HBM9378 Shows Sustained Asthma Control with Twice-Yearly Dosing Potential
The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. ...
September 10, 2026 | News
Accro, Fosun Pharma Secure China Nod for Phase II/III Trial of AC-201 in Vitiligo
Accro Bioscience (Suzhou) Limited ("Accro") today announced that Shanghai Fosun Pharmaceutical Industrial Development Company Limited ("Fosun Pharma Indust...
September 10, 2026 | News
CelluPro Becomes First Chinese Cell Culture Media Supplier to Secure EXCiPACT GMP Certification
CelluPro, a biotechnology company specializing in serum-free cell culture media and bioprocess solutions, has achieved EXCiPACT™ GMP Certif...
September 09, 2026 | News
CorrectSequence’s Base-Editing Therapy Shows Durable Response Across Diverse β-Hemoglobinopathy Patients
Following 100% transfusion independence in Chinese TDT patients, new study confirms tBE is equally safe and effective for African SCD patients and TDT pati...
September 09, 2026 | News
Clover Biopharmaceuticals Reports Positive Phase II Results for RSV-hMPV-PIV3 Combination Vaccines
-- Positive Phase 2 (Australia) results strengthen potential best-in-class profile of RSV+hMPV±PIV3 combination vaccines, with the potential differe...
September 08, 2026 | News
US FDA Clears Acepodia’s ACE723 IND for Phase I Trial in Liver Cancer
FDA clearance enables initiation of a Phase 1 clinical trial and advances the first AD2C-generated candidate into clinical development Acepodia (6976: TT)...
September 07, 2026 | News
Norroy Bioscience Secures China Clearance for Phase III Trial of PSMA-Targeted Radiopharmaceutical
NORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that it has received regu...
September 04, 2026 | News
Everest Medicines Secures China Approval for CARDAMYST to Treat Acute PSVT Episodes
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...
September 04, 2026 | News
Convergen Raises $15M Seed+ to Accelerate Targeted Protein Degradation Therapies
Convergen, a biotechnology company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, an...
September 02, 2026 | News
Thermo Fisher Strengthens China Focus as Biopharma Innovation Gains Global Momentum
Thermo Fisher Scientific is reinforcing its commitment to China as the country emerges as an increasingly important source of global biopharmaceutical inno...
September 01, 2026 | News
WuXi AppTec Raises 2026 Interim Dividend to RMB 1.51 Billion Amid Global CRDMO Expansion
WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organizati...
September 01, 2026 | News
DualityBio, Genentech Ink $1B-Plus Deal to Develop Next-Generation ADCs Against Drug-Resistant Tumours
Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, with Genentech assuming furth...
August 31, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
